Our previous studies suggested that the PDE4 inhibitor rolipram reversed Aβ1–42-induced memory impairment, as evidenced by increased crossing numbers and shorter latency to reach the target zone where the platform was removed in the test session (Xu et al., 2018). Here, PDE4A is linked to memory impairment.